AIX-EN-PROVENCE, France, Oct. 19, 2017 -- SuperSonic Imagine (Euronext:SSI) (FR0010526814), a company specializing in ultrasound medical imaging, announced today it will be exhibiting at The Liver Meeting, held at Walter E. Washington Convention Center, Washington, DC, October 20 – 24. The company will introduce the Aixplorer Ultimate, which is an image-guided non-invasive liver disease assessment system, during the American Association for the Study of Liver Diseases (AASLD) meeting.
“The Aixplorer Ultimate’s image-guided ShearWave™ Elastography (SWE™) technique enables physicians to measure tissue stiffness non-invasively with color-coded images acquired in just 60 seconds,” explains Alex Exposito, Director of North America at SuperSonic Imagine. “This evaluation of liver fibrosis severity* provides a highly accurate alternative to biopsy, without the high costs or risk of morbidity. This is particularly beneficial for patients with hepatitis C and other diseases that require repeated evaluations.”
The new Aixplorer Ultimate has expanded the technology evolution through innovation thanks to exclusive UltraFast™ technology. The Ultimate’s elegant new look and enhanced user interface make it simple to use. The system’s computation power is more than 4.5 times faster and 20% more energy efficient than its predecessor. Aixplorer Ultimate also includes a barcode scanner for inputting patient information, reducing manual errors and saving time.
With its new Aixplorer Ultimate and its exclusive UltraFast technology SuperSonic Imagine expands the platform, adding new innovative features, making exams easier, without compromising quality or performance. Non-invasive tools to evaluate liver stiffness and non-alcoholic steatohepatitis (NASH) assessment are at the point of care, making the procedure an extension of the clinical examination.
“We look forward to sharing the Aixplorer Ultimate’s capabilities at The Liver Meeting. With SWE technology, Gastroenterologists and Hepatologists can evaluate liver stiffness for the assessment of liver fibrosis* and NASH severity without a biopsy,” said SuperSonic Imagine CEO Michèle Lesieur.
More than 120 international publications agree that SuperSonic Imagine’s ShearWave Elastography has demonstrated reliability and effectiveness in the liver field.
Attendees can learn more about the Aixplorer Ultimate by visiting SSI at booth #306 throughout The Liver Meeting.
*Pending FDA 510k
About SuperSonic Imagine
Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. In addition to providing exceptional image quality, this unique technology is the foundation of several innovations which have changed the paradigm of ultrasound imaging: ShearWave™ Elastography (SWE™), UltraFast™ Doppler and more recently Angio PL.U.S – Planewave UltraSensitive™ Imaging. ShearWave Elastography allows physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This criteria has become an important parameter in diagnosing potentially malignant tissue or other diseased tissue. As of today, over 300 peer-reviewed publications have demonstrated the value of SWE for the clinical management of patients with a wide range of diseases. UltraFast Doppler combines Color Flow Imaging and Pulsed Wave Doppler into one simple exam, providing physicians with exam results simultaneously and helping to increase patient throughput. The latest innovation, Angio PL.U.S, provides a new level of microvascular imaging through significantly improved color sensitivity and spatial resolution while maintaining exceptional 2D imaging. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer in key global markets. SuperSonic Imagine is a listed company since April 2014 on the Euronext, symbol SSI. For more information about SuperSonic Imagine, please go to www.supersonicimagine.com.
Contact information:
SuperSonic Imagine
Marketing & Communication
Emmanuelle Vella
[email protected]
+33 4 86 79 03 27
NewCap
Investor Relations – EU
Pierre Laurent / Florent Alba
[email protected]
+33144719855
Pascale Communication
Media Relations - US
Amy Phillips
[email protected]
+1 412 327 9499


Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 



